![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhlgnk-QaJZ0nJtKkN0LAS1OMxsgZ9uVjlqet-8wUxDQtIvkDf4puXHBH1Y8BYH8ry6Sf6HRviqmrRgqV6hxS9-1EMEzqeMedRAllYY_QG3fiTdR7hc-Q_3lXwSdq4jiOoqPlRxIDfW9tM7/s320/PRTO2020051820200605-798673.png)
Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. It develops vonapanitase, a recombinant human elastase, which is in two Phase III clinical trials in patients with chronic kidney disease undergoing surgical creation of a radiocephalic arteriovenous fistula for hemodialysis; has completed a Phase I/II clinical trials for the treatment of patients undergoing arteriovenous graft placement; and has completed Phase I clinical trial for the treatment of symptomatic peripheral artery diseases. The company was founded in 2001 and is headquartered in Waltham, Massachusetts.
http://www.priceseries.com/trade/PRTO-Proteon-Therapeutics-Inc-stock-gains-95-percent-a-Trade-Record-by-priceSeries-2020051820200605.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments